Background: The objective of the study was to estimate the antitumor activity of pemetrexed in patients with advanced/recurrent carcinoma of the cervix and to determine the nature and degree of toxicity.
introduction
Cervical cancer is the second most common cancer of women and the leading cause of cancer death in women worldwide, with estimated 11 070 new cases and 3870 deaths in the United States for 2008 [1] . The majority of early-stage tumors [International Federation of Gynecology and Obstetrics (FIGO) 1A or 1B] are treated with surgery, while those presenting with locally advanced cancers are now given concurrent chemoradiation [2] or neoadjuvant chemotherapy or radiochemotherapy followed by surgery [2, 3] .
The recurrence rate of cervical cancer is between 10% and 20% for FIGO stages IB-IIA and 50%-70% in locally advanced disease. Advanced and/or recurrent cervical cancer not amenable to surgical or radiation treatment presents a poor prognosis with 1-year survival rate ranging between 15% and 20%. No potentially curative therapy yet exists and the focus of treatment is palliation of symptoms with chemotherapy. Cisplatin 50 mg/m 2 administered every 3 weeks has been for long time considered the standard treatment with response rates of 20%-30% and an overall survival (OS) of 7 months.
Actually, other drugs such as ifosfamide, paclitaxel, topotecan, vinorelbine, and gemcitabine have been found to have activity of interest as single agents . Combinations of these agents have been compared with single drug with improvements in response rates and progression-free survival (PFS) and recently, an improvement in OS has been registered with cisplatin and topotecan over cisplatin alone [31] [32] [33] [34] .
Pemetrexed (Alimta, LY231514; Eli Lilly, Florence, Italy) is an antifolate, antineoplastic agent that exerts its action by disrupting folate-dependent metabolic processes essential for cell replication. Pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), all folatedependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides [35] [36] [37] [38] [39] [40] . Pemetrexed in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma and as a single agent in the therapy for locally advanced or metastatic nonsmall-cell lung cancer (NSCLC). A recent single-institution phase I-II trial in chemotherapy-naive advanced/recurrent cervical cancer patients indicated possible activity for pemetrexed [41] .
The purpose of this study was to evaluate the antitumor activity of pemetrexed in patients with advanced or recurrent carcinoma of the cervix and to determine the nature and degree of toxicity of pemetrexed in this cohort of patients.
methods
Eligible patients had advanced or recurrent squamous or nonsquamous cell carcinoma of the cervix with documented disease progression after one prior treatment with cisplatin-based chemotherapy in combination or not with radiotherapy. Patients must have had measurable disease according to RECIST criteria definition (at least one lesion with >20 mm diameter when measured by conventional techniques or >10 mm when measured by spiral computed tomography) outside a previously irradiated field. Patients must have had only one prior systemic cisplatin-based chemotherapeutic regimen in conjunction or not with radiation. Patients must have had adequate bone marrow function as evidenced by an absolute neutrophil count >1500/ml, platelets >100 000/ml, and hemoglobin >9 g/dl. A calculated creatinine clearance >45 ml/min, using the standard Cockcroft and Gault formula, was required. Adequate hepatic function must have been demonstrated with a bilirubin <1.5· the upper limit of institutional normal and alkaline phosphatase, aspartate transaminase, and alanine transaminase <3· the upper limit of institutional normal. The study must have been approved by a local Institutional Ethical Committee (IEC) and patients must have signed an IEC-approved informed consent. Patients with a history of other invasive malignancies with the exception of nonmelanoma skin cancer were excluded if there was any evidence of other malignancy being present within the last 5 years. Patients unable to interrupt aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) 2 days before, the day of, and 2 days after the assumption of pemetrexed were ineligible. The presence of clinically relevant third-space fluid collections not controlled by drainage or other procedures also represented an exclusion criteria.
Pemetrexed at a dose of 500 mg/m 2 was to be administered as an i.v. taken the day prior, day of, and day after each dose of pemetrexed. NSAIDs were held for the 2 days before and after pemetrexed administration. Complete blood counts were obtained weekly. Cycles were repeated every 21 days if an absolute neutrophil count >1500/ml, a platelet count >1000/ml, and the resolution or reduction to grade 1 of non-hematologic toxic effects were registered. Weekly delays in therapy were prescribed to allow resolution of persistent hematologic and non-hematologic toxicity but patients were removed from study for delays in excess of 2 weeks. Adverse events were defined and graded according to the Common Terminology Criteria for Adverse Events version 3.0. Dose reduction was required for febrile neutropenia and/or grade 4 neutropenia persisting >7 days, grade 4 thrombocytopenia, or grade 3 thrombocytopenia associated with bleeding, and greater than grade 2 peripheral neuropathy. Prophylactic growth factors were not allowed while use of erythropoietin was permitted. Patients were treated until disease progression or intolerable toxicity precluding further treatment.
Response rate was evaluated for all measurable lesions according to RECIST criteria [42] .
The study employed a two-stage Simon accrual design with an early stopping rule in the event of insufficient activity demonstrated by the treatment. The percentage of objective response in patients with advanced or recurrent cervical cancer which failed a previous cisplatin-based chemotherapy treatment is 10%-15%. The hypothesis is that pemetrexed might obtain a response rate of 25% in patients with disease in not previously irradiated fields. During the first stage of accrual, 18 patients were to be entered and evaluated. If at least three responses were observed, a second phase of accrual was to be initiated which would increase accrual to 43 patients. The regimen would be considered active if at least seven responses were observed among 43 patients (a = 0.05; b = 0.20) [43] . Tables 1  and 2 , respectively. The median age of patients was 61 years (range 30-84). Most patients had a performance status (ECOG) original article Annals of Oncology of one (49%), squamous histology (67%), and grade 3 tumors (49%). All patients had received prior platinum-based combination therapy and 63% had prior radiation therapy. A total of 164 cycles (median, two per patient, range 1-9) of chemotherapy were administered (Table 3) . Hematological and non-hematological adverse events for all cycles are listed in Tables 4 and 5 , respectively. Overall, the treatment was well tolerated with the most common toxic effects being leucopenia, asthenia, and gastrointestinal toxic effects. More serious hematological toxic effects (grade 3-4) included anemia in 12%, leucopenia in 28%, neutropenia in 30%, and thrombocytopenia in 9% of patients. Among nonhematological toxic effects, grade 3-4 asthenia, anorexia, and diarrhea were registered in <4% of cycles. Grade 3 increase in alkaline phosphate and transaminases was reported in 7% of cycles. Three patients developed allergic reactions typically manifesting as a cutaneous pruriginous rash in the subsequent week of the infusion and easily resolved with local corticosteroid applications. No treatment-related deaths were reported. Supportive care is described in Table 6 .
Six patients (14%) had partial responses with a median duration of response of 7 weeks (range . No complete response (disappearance of all target lesions) was registered. Twenty-three patients (53%) had prolonged stabilization of disease lasting a median of 14.9 weeks (range 8-56). Fourteen patients (33%) had progressing disease ( Table 7 ). The median PFS was 10 weeks. The median OS was 35 weeks. Eighteen patients (42%) presented measurable lesions within the previously irradiated fields. Even if these lesions did not represent the target of the response for the protocol inclusion criteria, the registered response rate in the previously irradiated field was 7% (three patients, data not shown).
discussion
This study confirms the moderate activity of pemetrexed in advanced or recurrent cervical cancer after failing of prior cisplatin-based chemotherapy treatments.
Advanced cervical cancer not amenable of curative treatment with surgery or radiotherapy remains a poor prognosis disease; the median OS of recurrent cervical cancer patients is 6 months with only 20% of them alive at 1 year from the diagnosis of recurrence. There remains a lack of effective therapy against cancer of the uterine cervix that has metastasized to or recurred in sites not amenable of curative treatment and palliative chemotherapy, the only option we can offer, is active in only 10%-15% of patients.
Several phase II trials have identified potentially active chemotherapy agents including cisplatin and ifosfamide [4] [5] [6] , topotecan, gemcitabine, and vinorelbine [11, 12, 14, 17, 18] . In addition, potentially active combinations have been tested in the frontline setting. Ifosfamide, paclitaxel, topotecan, and vinorelbine in combination with cisplatin showed interesting activity [21, 23, [26] [27] [28] . Several of the agents and combinations found to have activity of interest have been compared in phase III trials [31] [32] [33] [34] . Cisplatin and paclitaxel was superior to cisplatin alone with respect to response rate and PFS with sustained quality of life [34] . Cisplatin and topotecan was the first combination chemotherapy to demonstrate a survival advantage over cisplatin alone in advanced cervical cancer in a randomized phase III trial [31] [32] [33] . Topotecan, gemcitabine, and vinorelbine were each combined with cisplatin in a recently completed randomized frontline trial (GOG 204); the study showed no difference between the treatment arms in terms of response rate, PFS, and OS, differing the combinations only in terms of toxicity profile [44] .
Pemetrexed (Alimta, LY231514) is an antifolate, antineoplastic agent that exerts its action by disrupting folatedependent metabolic processes essential for cell replication. In vitro studies have shown that pemetrexed inhibits TS, DHFR, and GARFT, all folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides. Pemetrexed is transported into cells by both the reduced folate carrier and membrane folate-binding protein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase. Polyglutamation is a time-and concentrationdependent process that occurs in tumor cells and, to a lesser extent, in normal tissues. Polyglutamate metabolites have an increased intracellular half-life resulting in prolonged drug action in malignant cells. Pemetrexed is approved in combination with cisplatin for treatment of malignant pleural mesothelioma and as single agent in recurrent NSCLC after prior chemotherapy.
Pemetrexed, administered as a single agent every 21 days at 500-600 mg/m 2 , has demonstrated activity in multiple tumor types, including mesothelioma, NSCLC, breast, colorectal, pancreas, bladder, head and neck, and cervical cancer [41, [45] [46] [47] .
Preliminary data from a single-institution phase II trial in a population of 34 inoperable, locally advanced, recurrent or metastatic chemotherapy-naive cervical cancer patients have reported an 18% response rate with a median duration of response of 3.8 months and a median OS of 15.2 months [41] .
Miller et al. [48] reported the results of a Gynecologic Oncology Group (GOG) phase II trial evaluating the activity of pemetrexed 900 mg/m 2 once every 21 days as second-line chemotherapy in a population of persistent or recurrent carcinoma of the cervix after failing of one prior systemic chemotherapy treatment . In this trial, pemetrexed was well tolerated and demonstrated moderate activity with a response of 15% in the general population; the response rates for nonradiated and radiated disease sites were 25% and 7%, respectively, with a PFS of 3.1 months and OS of 7.4 months. In our trial, pemetrexed at the dose of 500 mg/m 2 every 21 days was well tolerated and demonstrated moderate activity with a response rate of 14%, comparable to the results previously reported for this drug and for all other drugs employed in the treatment of recurrent cervical cancer (Table 8 ) [9] . Also, the PFS of 10 weeks and the OS of 35 weeks appear in line with what we can generally expect in this subset population.
With respect to the GOG study, our response rates in not previously irradiated patients appear quite lower. This may be due to the different dosages utilized in the trials (at the timeour trial started, the only phase II study published indicated the dose of 500 mg/ml q 21 days for pemetrexed [41] ) and to the worse prognostic factors of our population in which 33% presented with cervical adenocarcinoma and 49% with undifferentiated tumor at recurrences; 48% were FIGO stages III and IV at diagnosis and 70% recurred with distant metastasis.
The very favorable toxicity profile and the documented in vitro synergism with cisplatin may favor the evaluation of this pemetrexed-platinum combination treatment in recurrent cervical cancer patients and also in neoadjuvant setting in combination or not with radiotherapy [45, 46, [49] [50] [51] . 
